AzTrials
AzTrials

HealthyNCT04234529

Impact of AMATEA™️ on Physiological Measures and Gaming Performance in Active Gamers: a Placebo Controlled, Double-blind, Randomized Study

A study testing AMATEA™ and Caffeine in people with Healthy, run by University of Memphis at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

AMATEA™ is a patented dietary supplement consisting of a unique blend of caffeine and polyphenol antioxidants; standardized at 20% caffeine, 30% chlorogenic acids (similar to green coffee). Read more about this study

Who is it for?
Ages 18 to 40 yearsHealthy volunteers can take part
Conditions the study is for
Healthy
What is being tested?
AMATEA™ and Caffeine
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
59 participants
Where
1 siteUnited States
Study dates
1 Feb 2020to 11 Jun 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • age 18-40 years
  • male or female
  • body mass index (BMI) between 18-34.9 kg/m2
  • not be using tobacco products
  • no diagnosed history of diabetes
  • no diagnosed history of cardiovascular disease
Show all 15Show fewer
  • no diagnosed history of neurological disease
  • no consumption of alcohol within 48 hours of testing
  • consume < 400mg caffeine daily
  • no consumption of caffeine-containing beverages within at least 48 hours of testing
  • blood metabolic parameters within normal limits
  • if female, not be pregnant
  • active gamers: playing at least 4 days per week, for at least 4 hours per day, for the past 12 months
  • regularly playing the game Fortnite, for the past 3 months
  • willing to play on our console systems and use their personal headset

Who cannot join

  • individuals younger than 18 years or greater than 40 years
  • individuals weighing less than 115 pounds
  • individuals with a BMI less than 18kg/m2 or greater than 35kg/m2
  • individuals with a diagnosed history of diabetes, cardiovascular disease, or neurological disease
  • individuals that consume greater than 400mg caffeine daily
  • pregnant females
  • non-active gamers

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Center for Nutraceutical and Dietary Supplement Research

    Memphis, Tennessee, 38152

Other trials in United States

About this study

AMATEA™ is a patented dietary supplement consisting of a unique blend of caffeine and polyphenol antioxidants; standardized at 20% caffeine, 30% chlorogenic acids (similar to green coffee). In-house evaluations and anecdotal findings related to AMATEA have noted sustained energy without the typical "crash" and/or "jitters" experienced by some with caffeine ingestion alone.

The aim of the present study is to compare the effects of AMATEA and caffeine alone on various measures of cognitive performance, mood, and gaming performance in men and women who regularly engage in gaming activity. The investigators hypothesize that both AMATEA and caffeine will improve outcome measures more than placebo, with greater improvement noted for the AMATEA condition due to the addition of the chlorogenic acid.

Read the detailed description

The activity of "gaming" is increasing in popularity each year, with millions of young adults engaged in regular play. This has fueled the rise in nutrition and dietary supplementation strategies to aid gaming performance. Since caffeine has been widely used for purposes of improving athletic performance with both relatively low and high dosages, and more recently as a potential aid for "mind" games such as chess at a dosage of 400mg, this has been the nutrient of focus for many gamers. Other multi-component products are making their way to the market.

Active gamers claim to ingest such products regularly throughout their gameplay, which can span from 4-12 hours per session for regular gamers. AMATEA™ is a patented dietary supplement consisting of a unique blend of caffeine and polyphenol antioxidants; standardized at 20% caffeine, 30% chlorogenic acids (similar to green coffee). The product is also Generally Recognized as Safe (GRAS) and USDA organic.

While caffeine has been well-investigated for its performance boosting effects, chlorogenic acid has been reported to offer many potential health benefits. Specifically, it has been reported to improve select cognitive measures following regular intake, which may translate into more efficient performance with complex tasks-such as those involved with gaming.

In-house evaluations and anecdotal findings related to AMATEA have noted sustained energy without the typical "crash" and/or "jitters" experienced by some with caffeine ingestion alone. While caffeine can prove beneficial to many, some users experience "crashing" 2-3 hours post ingestion, while others feel too "wired" following use and may experience difficulty concentrating. AMATEA contains a relatively low concentration of caffeine per capsule (150mg) in an attempt to avoid such problems, while also containing chlorogenic acid. This may aid gamers who need to maintain fine motor skills and those who need to concentrate on complex activities for several hours continuously.

The aim of the present study is to compare the effects of AMATEA and caffeine alone on various measures of cognitive performance, mood, and gaming performance in men and women who regularly engage in gaming activity. The investigators hypothesize that both AMATEA and caffeine will improve outcome measures more than placebo, with greater improvement noted for the AMATEA condition due to the addition of the chlorogenic acid.

Conditions
Healthy
Being tested
AMATEA™, Caffeine, Placebo
Keywords
AMATEA, video games, gaming, energy supplement

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AMATEA™Dietary supplement

    AMATEA™ is a patented dietary supplement consisting of a unique blend of caffeine and polyphenol antioxidants; standardized at 20% caffeine, 30% chlorogenic acids (similar to green coffee).

    Total of 1.35g of AMATEA containing 270mg of caffeine.

  • CaffeineDietary supplement

    1.08g of microcellulose and 270mg of caffeine.

  • PlaceboOther

    1.35g of microcellulose

Study groups in NCT04234529
Study groupRoleWhat they receive
AMATEAActive comparator3x 450mg capsules of AMATEA which contains 270mg of caffeine total
Receives: Dietary Supplement: AMATEA™
CaffeineActive comparator3x 450mg capsules each containing 360mg of microcellulose and 90mg of caffeine (270mg caffeine total)
Receives: Dietary Supplement: Caffeine
PlaceboPlacebo comparator3x 450mg capsules of microcellulose
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Fortnite Gaming metrics with AMATEA

    We will determine the change in the Fortnite gaming metrics report following 4 hours of play when taking AMATEA versus placebo or caffeine

    Measured: During 4 hours of gaming following AMATEA ingestion

  2. Fortnite Gaming metrics with caffeine

    We will determine the change in the Fortnite gaming metrics report following 4 hours of play when taking caffeine versus placebo or AMATEA

    Measured: During 4 hours of gaming following caffeine ingestion

  3. Fortnite Gaming metrics with placebo

    We will determine the change in the Fortnite gaming metrics report following 4 hours of play when taking placebo versus AMATEA or caffeine

    Measured: During 4 hours of gaming following placebo ingestion

  4. Change in mental performance from baseline with AMATEA

    We will determine the change in daily mental performance assessed via AX-CPT when taking AMATEA versus caffeine or placebo

    Measured: Prior to and during the 6 hour period following AMATEA ingestion

  5. Change in mental performance from baseline with caffeine

    We will determine the change in daily mental performance assessed via AX-CPT when taking caffeine versus caffeine or AMATEA

    Measured: Prior to and during the 6 hour period following caffeine ingestion

  6. Change in mental performance from baseline with placebo

    We will determine the change in daily mental performance assessed via AX-CPT when taking placebo versus caffeine or AMATEA

    Measured: Prior to and during the 6 hour period following placebo ingestion

  7. Change in blood cortisol from baseline with AMATEA

    We will determine the change in daily blood cortisol when taking AMATEA versus caffeine or placebo

    Measured: Prior to and during the 6 hour period following AMATEA ingestion

  8. Change in blood cortisol from baseline with caffeine

    We will determine the change in daily blood cortisol when taking caffeine versus AMATEA or placebo

    Measured: Prior to and during the 6 hour period following caffeine ingestion

  9. Change in blood cortisol from baseline with placebo

    We will determine the change in daily blood cortisol when taking placebo versus AMATEA or caffeine

    Measured: Prior to and during the 6 hour period following placebo ingestion

  10. Change in digital symbol substitution from baseline with AMATEA

    We will determine the change in digital symbol substitution when taking AMATEA versus caffeine or placebo

    Measured: Prior to and during the 6 hour period following AMATEA ingestion

  11. Change in digital symbol substitution from baseline with caffeine

    We will determine the change in digital symbol substitution when taking caffeine versus AMATEA or placebo

    Measured: Prior to and during the 6 hour period following caffeine ingestion

  12. Change in digital symbol substitution from baseline with placebo

    We will determine the change in digital symbol substitution when taking placebo versus AMATEA or caffeine

    Measured: Prior to and during the 6 hour period following placebo ingestion

  13. Change in reaction time from baseline with AMATEA

    We will determine the change in reaction time when taking AMATEA versus caffeine or placebo

    Measured: Prior to and during the 6 hour period following AMATEA ingestion

  14. Change in reaction time from baseline with caffeine

    We will determine the change in reaction time when taking caffeine versus AMATEA or placebo

    Measured: Prior to and during the 6 hour period following caffeine ingestion

  15. Change in reaction time from baseline with placebo

    We will determine the change in reaction time when taking placebo versus AMATEA or caffeine

    Measured: Prior to and during the 6 hour period following placebo ingestion

Secondary outcomes (8)
  1. Heart rate

    Change in heart rate each hour after ingestion

    Measured: Prior to and during the 6 hour period following supplement/placebo ingestion

  2. Blood pressure

    Change in blood pressure each hour after ingestion

    Measured: Prior to and during the 6 hour period following supplement/placebo ingestion

  3. Rate pressure product

    Change in rate pressure product each hour after ingestion

    Measured: Prior to and during the 6 hour period following supplement/placebo ingestion

  4. Digital symbol substitution test

    Change in digital symbol substitution test each hour after ingestion

    Measured: Prior to and during the 6 hour period following supplement/placebo ingestion

  5. Brunel Mood Score

    Change in Brunel Mood Score (Brums-32) using a scale 0 (Not at all) to 4 (Extremely) with higher scores indicating stronger feelings each hour after ingestion

    Measured: Prior to and during the 6 hour period following supplement/placebo ingestion

  6. Subjective Mood

    Change in subjective mood using a visual analog schedule running from None to Extreme, where values nearer extreme indicate stronger feelings each hour after ingestion

    Measured: Prior to and during the 6 hour period following supplement/placebo ingestion

  7. Reaction time

    Change in reaction time each hour after ingestion

    Measured: Prior to and during the 6 hour period following supplement/placebo ingestion

  8. Blood cortisol

    Change in blood cortisol from baseline every 2 hours after ingestion for 4 hours

    Measured: Prior to and during the 6 hour period following supplement/placebo ingestion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jan 2020
  2. Study start1 Feb 2020
  3. Primary completion11 Jun 2021
  4. Study completion11 Jun 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Model description
Participants will receive each of the 3 interventions over a 3 week period i.e. one acute dose once per week. The 3 interventions include 1) AMATEA, 2) Caffeine, or 3) Placebo
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
59 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04234529
Sponsor's protocol ID
PRO-FY2020-65
Status last verified
Dec 2021
First submitted
9 Dec 2019
Last updated
9 Dec 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing AMATEA™ and Caffeine in people with Healthy, run by University of Memphis at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Fortnite Gaming metrics with AMATEA (time frame: During 4 hours of gaming following AMATEA ingestion). The study lists 15 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Dec 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in